New Class of Cholesterol-Lowering Drugs Promising for Previously Intolerant Patients

A modestly sized clinical trial indicates that PCSK9-inhibitors can help lower cholesterol, even for those who experienced side effects with older drugs.

1:00 PM

Author | Shantell M. Kirkendoll

Millions of adults rely on statins to control their cholesterol. Researchers are now paying closer attention to those who've missed out on the drugs' benefits because of intolerances.

In a clinical trial, Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3, or GAUSS-3, a new class of drugs called PCSK9-inhibitors had a positive impact on treating hyperlipidemia in adults who cannot take statins due to muscle-related side effects.

But the big PCSK9-inhibitor question in the medical community is whether the cholesterol-lowering effect shown by these drugs can translate to fewer cardiovascular events.

"This was a modest trial of about 200-plus patients. It hasn't been powered to look at the end points that we really care about like heart attack, angina, cardiovascular death and stroke," University of Michigan Frankel Cardiovascular Center cardiologist Kim Eagle, M.D., says. Eagle was part of a panel that reviewed the results presented as a late-breaking trial during the American College of Cardiology Scientific Sessions.

What was shown in the initial trial, though, makes PCSK9-inhibitors an attractive option for lowering cholesterol in those who are statin intolerant, Eagle says. The findings are published in JAMA: Journal of the American Medical Association.

It looks to be interesting in terms of this class of agents being very attractive for that large cohort of patients with statin intolerance.
Kim Eagle, M.D.

Improvements in mean LDL cholesterol

Statins have a long track record of lowering cholesterol and reducing cardiovascular events. But a reported 5 to 20 percent of patients cannot tolerate them because of muscle-related side effects, including muscle aches and spasms.

In the trial in patients with statin intolerance due to muscle-related adverse effects, the high-profile PCSK9 drug evolocumab (Repatha) cut mean LDL cholesterol significantly further than ezetimibe, a well-known cholesterol drug, over 24 weeks.

Evolocumab is designed to bind to PCSK9 and inhibit the protein from binding to LDL receptors on the liver surface. In the absence of PCSK9, there are more LDL receptors on the surface of the liver to remove LDL-C from the blood. In contrast, statins slow down production of cholesterol in the liver by blocking the enzyme that creates cholesterol.

Study participants with confirmed statin intolerance started with a mean LDL-C of 219.9. That number dropped by more than 54.5 percent for the study group taking evolocumab, compared to a 31.2 percent reduction in the ezetimibe group.

Muscle symptoms were reported in 28.8 percent of ezetimibe-treated patients and 20.7 percent of evolocumab-treated patients.

One patient, representing less than 1 percent of those taking evolocumab in the trial, had to stop taking the medicine because of muscle symptoms compared to 6.8 percent of ezetimibe-treated patients. 

"It looks to be interesting in terms of this class of agents being very attractive for that large cohort of patients with statin intolerance," Eagle says.

Up next, the drug developer Amgen is sponsoring a large cardiovascular outcomes trial to examine the impact of PCSK9 on cardiac events. Results of that study are expected no later than 2017.

More Articles About: Body Work Preventive Cardiology Cardiovascular: Preventive Cardiology
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories surgeons in OR with blue and teal scrubs with screen on and patient under teal sheet
Health Lab
Treating heart valve disease: What are your options?
Michigan Medicine’s head of cardiac surgery, Gorav Ailawadi, M.D, M.B.A., answers questions about different treatment options for heart valve disease.
heart organ yellow blue
Health Lab
Older adults from distressed communities attend less cardiac rehab after heart procedures
Older adults who live in disadvantaged communities are less likely to attend cardiac rehabilitation after common heart procedures, a Michigan Medicine-led study finds.
watch on hand
Health Lab
Tailored text messages not enough to improve mobility after heart issues
A Michigan Medicine report shows that adding a mobile health application to such devices yields mixed results. Tailored text messages to encourage high-risk people to move more may improve some short-term outcomes but doesn’t always improve physical activity levels for everyone.
man smiling sitting
Health Lab
A unique collaboration helps one patient better manage aortic disease
MI-AORTA is a donor-funded initiative that facilitates collaboration within the Frankel Cardiovascular Center, U-M Health and referring provider networks, creating value for the patients, families, and communities they serve and allows them to continue to pioneer advanced therapies for aortic diseases.
woman checking watch orange shirt outside
Health Lab
Increased step count linked to better health for people with heart failure
Using these wearable devices, a study led by Michigan Medicine and the University of Missouri with Saint Luke’s Mid America Heart Institute finds that taking more daily steps is associated improved health, including fewer symptoms and physical limitations, for people with heart failure.
person walking on treadmill
Health Lab
Cardiac rehabilitation reduces risk of death years after heart surgery, still underutilized
A Michigan Medicine study finds people who participate in cardiac rehabilitation have a decreased risk of death years after surgery, with a trend towards better outcomes in patients who attend more sessions.